



InteliCare Holdings Ltd
ABN 84 622 484 397

ASX Code
ICR

Corporate Directory

Non-Executive Chair
Dr Neale Fong

Non-Executive Director
Mr Greg Leach

Non-Executive Director
Mr Tim Chapman

Company Secretary
Mr Neil Hackett

Chief Executive Officer
Mr Daniel Pilbrow

Issued Shares
487,338,144

Unlisted Options
146,636,458

Listed Options
74,824,568

Company Details

Email
investors@intelicare.com.au

Website
www.intelicare.com.au

Registered & Principal Office

Level 1, 299 Vincent St
Leederville WA 6001

\$1 million in funding secured to continue scale up of InteliCare platform

InteliCare Holdings Ltd (“**ICR**” or the “**Company**”) (ASX: ICR), an Australian Software-as-a-Service (**SaaS**) technology company commercialising its proprietary AI driven InteliCare platform (**InteliCare**) in the aged care, disability and health sectors, is pleased to announce that it has secured \$1 million in additional funding through a structured financing approach with the support of key existing shareholders. This funding will provide cash runway into 2026 allowing the Company to continue to scale up existing deployments as well execute on further potential contracts within the current sales pipeline.

The structured financing has been completed in two parts, with the establishment of a \$600,000 convertible note facility as well as the completion of a \$400,000 R&D loan.

Daniel Pilbrow, InteliCare CEO, commented, “I’m delighted to have secured this additional funding as this pivotal time in the commercialisation and scale up of the InteliCare platform. With our largest deployment at Hardi Aged Care continuing to scale as well as our key trial deployment at mecwacare’s Trescowthick facility expected to go live shortly, the evidence base and value proposition of our solution will continue to expand and deepen.

Not only does this additional funding provide necessary resources to support key existing deployments, it also allows us to execute on further commercial opportunities within our commercial pipeline as well as continue strategic partnership and investment discussions. It’s an incredibly exciting period for the Company.”

Within the structured financing the Company has entered into a \$600,000 convertible note facility with several professional and sophisticated investors (**Facility**). The Company may draw funds under the Facility in tranches of at least \$50,000 in return for the issuance of unsecured convertible notes with an equivalent face value (**Notes**). The Facility is for a term of 6 months which may be extended by the Company with consent of the subscribers (not to be unreasonably withheld) (**Term**).

The Notes accrue interest at a rate of 15% per annum for the duration of the Term, following which the Company will seek shareholder approval to convert the Notes and accrued interest into shares at a conversion price of \$0.007 per share. Each Conversion Share will be accompanied by one free attaching unquoted option with an exercise price of \$0.02 each and an expiry date of 4 years from the date of issue. A summary of the material terms of the Notes is in Schedule 1. Westar Capital acted as lead manager to the funding facility and will receive 6% on the gross proceeds of the total amount drawn down under the facility.

For personal use only

To complement the convertible note facility the Company has entered into another R&D loan with Rockford Equity Pty Ltd (**Rockford**). The loan is for \$400,000 secured against claimable R&D spend to be undertaken up to the end of 2025 and included in the FY2026 Company tax return. Additionally, under this loan agreement, Rockford has an election option whereby it can elect to convert up to \$200,000 of the R&D loan into shares in the Company at a \$0.007 conversion price for which an attaching option will be granted with a \$0.02 exercise price and a 3 year expiry from the date of issue. If Rockford elects to convert part of the loan, the Company will seek shareholder approval to undertake the issue. A summary of the material terms are included in schedule 2.

This announcement is approved for release by the Board of IntelliCare Holdings Limited.

For more information regarding IntelliCare, visit www.intellicare.com.au.

Contact and Authorised for Release to the ASX

Daniel Pilbrow, Chief Executive Officer, IntelliCare Holdings Ltd, +61 1300 001 145, investors@intellicare.com.au

About Intellicare Holdings Limited

IntelliCare is an Australian technology company that has commercialised a predictive analytics hardware and software system for use in the aged care and health industries. IntelliCare believes Australians deserve to age with dignity and through its business-to-business (B2B) and business-to-consumer (B2C) solutions built on its proprietary internet of things (IOT) platform utilising smart sensors and artificial intelligence (AI), IntelliCare aims to enable people to stay in their own homes for longer while empowering healthcare providers to deliver higher quality, more efficient services.

Schedule 1 – Convertible Note terms

Facility Amount	A\$600,000
Face Value	A\$1.00 per Note
Number of Notes	600,000 Notes
Drawdown	<p>(a) The Company may, at its option and at any time prior to the Maturity Date, drawdown the Facility Amount in one or more tranches of at least \$50,000 (Drawdown).</p> <p>(b) The Company shall be deemed to have issued that number of Notes as at the date of Drawdown as equates to the amounts drawn (on the basis of 1 Note for each \$1.00).</p>
Conversion Price	\$0.007 per Share
Attaching Options	Each Conversion Share will be accompanied by one free attaching unquoted option with an exercise price of \$0.02 each and an expiry date of 3 years from the date of issue (together, the Conversion Securities).
Conversion	(a) The Company must convene a general meeting within 45 days after the Maturity Date for the purpose of seeking shareholder approval under Listing Rule 7.1 to issue the Conversion Securities (Shareholder Approval).

For personal use only

	(b) The Company and subscribers may agree to convert the Notes prior to the Maturity Date subject to obtaining shareholder approval.
Interest	Simple interest will accrue daily on the Notes at the rate of 15% per annum from the date of issue.
Maturity Date	6 months from the commencement of the Facility.
Redemption	<p>(a) The Notes are repayable in cash in the event that the Shareholder Approval is not obtained.</p> <p>(b) The Noteholder may elect to redeem the Notes prior to the Maturity date in the following circumstances:</p> <ul style="list-style-type: none"> (i) the occurrence of an event of default by the Company; or (ii) the Company completing a capital raising of not less than \$2.5 million.

Schedule 2 – R&D Loan

Loan Amount	A\$400,000
Interest Rate	15% pa
Maturity	Minimum Term will be 180 days from the date of this agreement with 553 days being the end date of the loan agreement
Conversion Option	Under the terms of the loan Rockford has an election right to convert up to \$200,000 of this loan on conversion terms agreed
Conversion Price	\$0.007 per Share
Attaching Options	Each Conversion Share will be accompanied by one free attaching unquoted option with an exercise price of \$0.02 each and an expiry date of 3 years from the date of issue (together, the Conversion Securities).
Conversion	The Company must convene a general meeting within 60 days after the receiving the conversion notice for the purpose of seeking shareholder approval under Listing Rule 7.1 to issue the Conversion Securities.